Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBIO NASDAQ:MEIP NASDAQ:NATR NASDAQ:OVID NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBIOFortress Biotech$2.82+3.3%$2.91$1.33▼$4.20$81.23M1.751.47 million shs391,326 shsMEIPMEI Pharma$3.19+14.7%$3.98$1.46▼$9.00$104.72M0.381.15 million shs3.98 million shsNATRNature's Sunshine Products$14.86+0.9%$16.21$11.01▼$18.06$259.78M1.1290,129 shs77,430 shsOVIDOvid Therapeutics$1.65-5.7%$1.25$0.24▼$2.01$124.44M0.355.58 million shs1.64 million shsSPROSpero Therapeutics$2.49+5.5%$2.03$0.51▼$3.22$132.81M1.47406,163 shs591,929 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBIOFortress Biotech+3.30%-3.09%-20.56%+46.11%+63.95%MEIPMEI Pharma0.00%0.00%0.00%-29.13%+17.68%NATRNature's Sunshine Products+0.88%-0.93%-12.64%+1.23%+15.02%OVIDOvid Therapeutics-5.71%+4.43%+28.91%+244.25%+43.48%SPROSpero Therapeutics+5.51%+9.21%+32.45%+0.40%+107.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBIOFortress Biotech$2.82+3.3%$2.91$1.33▼$4.20$81.23M1.751.47 million shs391,326 shsMEIPMEI Pharma$3.19+14.7%$3.98$1.46▼$9.00$104.72M0.381.15 million shs3.98 million shsNATRNature's Sunshine Products$14.86+0.9%$16.21$11.01▼$18.06$259.78M1.1290,129 shs77,430 shsOVIDOvid Therapeutics$1.65-5.7%$1.25$0.24▼$2.01$124.44M0.355.58 million shs1.64 million shsSPROSpero Therapeutics$2.49+5.5%$2.03$0.51▼$3.22$132.81M1.47406,163 shs591,929 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBIOFortress Biotech+3.30%-3.09%-20.56%+46.11%+63.95%MEIPMEI Pharma0.00%0.00%0.00%-29.13%+17.68%NATRNature's Sunshine Products+0.88%-0.93%-12.64%+1.23%+15.02%OVIDOvid Therapeutics-5.71%+4.43%+28.91%+244.25%+43.48%SPROSpero Therapeutics+5.51%+9.21%+32.45%+0.40%+107.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBIOFortress Biotech 2.33Hold$16.50485.11% UpsideMEIPMEI Pharma 0.00N/AN/AN/ANATRNature's Sunshine Products 2.67Moderate Buy$20.5037.95% UpsideOVIDOvid Therapeutics 2.86Moderate Buy$3.70124.24% UpsideSPROSpero Therapeutics 2.17Hold$5.00100.80% UpsideCurrent Analyst Ratings BreakdownLatest FBIO, NATR, MEIP, SPRO, and OVID Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025SPROSpero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025OVIDOvid TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/9/2025OVIDOvid TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.0010/8/2025FBIOFortress BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NATRNature's Sunshine ProductsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025OVIDOvid TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SPROSpero TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025SPROSpero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025FBIOFortress BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NATRNature's Sunshine ProductsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025OVIDOvid TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBIOFortress Biotech$57.67M1.45N/AN/A($0.06) per share-47.00MEIPMEI PharmaN/AN/A$6.25 per share0.51$4.96 per shareN/ANATRNature's Sunshine Products$460.82M0.57$1.26 per share11.79$8.71 per share1.71OVIDOvid Therapeutics$6.65M17.64N/AN/A$0.96 per share1.72SPROSpero Therapeutics$34.09M4.11N/AN/A$0.85 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBIOFortress Biotech-$46M-$1.05N/AN/AN/A-24.84%-301.81%-27.48%11/13/2025 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%N/ANATRNature's Sunshine Products$7.70M$0.7420.08∞N/A3.06%10.19%6.71%11/6/2025 (Estimated)OVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)SPROSpero Therapeutics-$68.57M-$0.98N/AN/AN/A-110.35%-120.27%-55.61%11/13/2025 (Estimated)Latest FBIO, NATR, MEIP, SPRO, and OVID EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025FBIOFortress Biotech-$0.32N/AN/AN/AN/AN/A11/13/2025Q3 2025SPROSpero Therapeutics-$0.25N/AN/AN/AN/AN/A11/11/2025Q3 2025OVIDOvid Therapeutics-$0.15N/AN/AN/A$0.17 millionN/A11/6/2025Q3 2025NATRNature's Sunshine Products$0.18N/AN/AN/A$119.39 millionN/A8/14/2025Q2 2025FBIOFortress Biotech-$0.31-$0.46-$0.15$0.45$14.53 million$16.41 million8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 million8/12/2025Q2 2025SPROSpero Therapeutics-$0.38-$0.03+$0.35-$0.03$11.00 million$14.19 million7/31/2025Q2 2025NATRNature's Sunshine Products$0.1650$0.35+$0.1850$0.28$113.10 million$114.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFBIOFortress BiotechN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ANATRNature's Sunshine Products$0.402.69%N/A54.05%N/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.062.41%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBIOFortress Biotech1.341.921.70MEIPMEI PharmaN/A16.7816.78NATRNature's Sunshine ProductsN/A2.271.35OVIDOvid Therapeutics0.234.724.72SPROSpero TherapeuticsN/A3.973.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBIOFortress Biotech96.51%MEIPMEI Pharma52.38%NATRNature's Sunshine Products79.40%OVIDOvid Therapeutics72.24%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipFBIOFortress Biotech27.90%MEIPMEI Pharma3.12%NATRNature's Sunshine Products4.70%OVIDOvid Therapeutics13.10%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBIOFortress Biotech17029.75 million21.45 millionOptionableMEIPMEI Pharma10032.84 million31.81 millionOptionableNATRNature's Sunshine Products85017.64 million16.81 millionOptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableSPROSpero Therapeutics15056.28 million53.18 millionOptionableFBIO, NATR, MEIP, SPRO, and OVID HeadlinesRecent News About These CompaniesZacks Research Downgrades Spero Therapeutics (NASDAQ:SPRO) to HoldOctober 15 at 7:45 AM | marketbeat.comSpero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeekOctober 14 at 8:00 AM | globenewswire.comBest Momentum Stock to Buy for October 10thOctober 10, 2025 | zacks.comSpero Therapeutics' (SPRO) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Rating Increased to Strong-Buy at Zacks ResearchOctober 8, 2025 | marketbeat.comAnalysts Set Spero Therapeutics, Inc. (NASDAQ:SPRO) PT at $5.00October 6, 2025 | americanbankingnews.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Receives Consensus Rating of "Hold" from BrokeragesOctober 3, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest UpdateSeptember 16, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Director Sells $12,946.84 in StockSeptember 4, 2025 | insidertrades.comDown 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a TurnaroundAugust 19, 2025 | zacks.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 13, 2025 | finanznachrichten.deSpero Therapeutics Reports Q2 2025 Results and Trial SuccessAugust 13, 2025 | msn.comSpero Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comSpero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comSpero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comSpero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025August 5, 2025 | globenewswire.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28, 2025 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025ISRG, TEAM, SFM Trade Well Below Highs With 30%+ UpsideBy Leo Miller | September 23, 2025Sprouts, Darden Offer High-Upside Setups for Risk-TakersBy Sam Quirke | September 26, 20253 Reasons to Buy Sprouts Farmers Market Ahead of EarningsBy Sam Quirke | October 12, 2025FBIO, NATR, MEIP, SPRO, and OVID Company DescriptionsFortress Biotech NASDAQ:FBIO$2.82 +0.09 (+3.30%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$2.80 -0.01 (-0.53%) As of 05:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.MEI Pharma NASDAQ:MEIPMEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Nature's Sunshine Products NASDAQ:NATR$14.86 +0.13 (+0.88%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$14.88 +0.03 (+0.17%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Ovid Therapeutics NASDAQ:OVID$1.65 -0.10 (-5.71%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$1.72 +0.07 (+4.18%) As of 04:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Spero Therapeutics NASDAQ:SPRO$2.49 +0.13 (+5.51%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$2.48 -0.01 (-0.40%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
